Prognostic Significance of HLA Class I Expression in Ewing's Sarcoma Family of Tumors

被引:32
|
作者
Yabe, Hiroki [2 ]
Tsukahara, Tomohide
Kawaguchi, Satoshi [1 ]
Wada, Takuro
Torigoe, Toshihiko [3 ]
Sato, Noriyuki [3 ]
Terai, Chihiro [2 ]
Aoki, Masaya [4 ]
Hirose, Shigemichi [5 ]
Morioka, Hideo [6 ]
Yabe, Hiroo [6 ]
机构
[1] Sapporo Med Univ, Dept Orthopaed Surg, Sch Med, Chuo Ku, Sapporo, Hokkaido 0608543, Japan
[2] Jichi Med Univ, Div Rheumatol, Saitama Med Ctr, Saitama, Japan
[3] Sapporo Med Univ, Dept Pathol, Sch Med, Sapporo, Hokkaido 0608543, Japan
[4] Natl Sanat Tama Zenshoen, Div Clin Lab, Tokyo, Japan
[5] Keio Univ, Sch Med, Dept Diagnost Pathol, Tokyo, Japan
[6] Keio Univ, Sch Med, Dept Orthopaed Surg, Tokyo, Japan
关键词
Ewing's; sarcoma; ESFT; HLA class I; CD8; T lymphocyte; CHILDRENS-ONCOLOGY-GROUP; NEUROECTODERMAL TUMOR; MONOCLONAL-ANTIBODY; ANTIGEN-EXPRESSION; DOWN-REGULATION; POOR-PROGNOSIS; CELL CARCINOMA; CHEMOTHERAPY; IMMUNOTHERAPY; CANCER;
D O I
10.1002/jso.21829
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Ewing's sarcoma family of tumors (ESFT) is one of the most malignant groups of tumors in young people. Human leukocyte antigen (HLA) class I displays endogenously processed peptides to CD8+ T lymphocytes and has a key role for host immune surveillance. In ESFT, the investigation concerning both HLA class I expression and T-cell infiltration has yet to be reported. Methods: Biopsy specimens from 28 ESFT patients were evaluated by immunohistochemistry with the anti-HLA class I monoclonal antibody (mAb) EMR8-5 and anti-CD8 mAb, respectively. Results: Expression of HLA class I was negative in 10 tumors and down-regulated in 22 tumors. The status of CD8+ T cell infiltration was closely associated with the expression levels of HLA class I. ESFT patients with down-regulated or negative expression of HLA class I showed significantly poorer survival than the rest of the patients. Conclusions: Our results suggested that CD8+T cell-mediated immune response restricted by HLA class I might play an important role in immune surveillance of ESFT, and we revealed for the first time that the status of HLA class I expression affects the survival of the patients with ESFT. J. Surg. Oncol. 2011; 103: 380-385. (C) 2010 Wiley-Liss, Inc.
引用
收藏
页码:380 / 385
页数:6
相关论文
共 50 条
  • [21] Ewing sarcoma family of tumors
    Khoury, JD
    ADVANCES IN ANATOMIC PATHOLOGY, 2005, 12 (04) : 212 - 220
  • [22] Ewing Sarcoma Family of Tumors
    Maheshwari, Aditya V.
    Cheng, Edward Y.
    JOURNAL OF THE AMERICAN ACADEMY OF ORTHOPAEDIC SURGEONS, 2010, 18 (02) : 94 - 107
  • [23] Ewing Sarcoma Family of Tumors
    Puchalski, Amy
    JOURNAL OF DIAGNOSTIC MEDICAL SONOGRAPHY, 2010, 26 (05) : 238 - 244
  • [24] Ewing's sarcoma and primitive neuroectodermal family of tumors
    Carvajal, R
    Meyers, P
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2005, 19 (03) : 501 - +
  • [25] Ewing's sarcoma family of tumors: Current management
    Bernstein, Mark
    Kovar, Heinrich
    Paulussen, Michael
    Randall, R. Lor
    Schuck, Andreas
    Teot, Lisa A.
    Juergens, Herbert
    ONCOLOGIST, 2006, 11 (05): : 503 - 519
  • [26] Prognostic factors for local and distant control in Ewing sarcoma family of tumors
    Rodriguez-Galindo, C.
    Navid, F.
    Liu, T.
    Billups, C. A.
    Rao, B. N.
    Krasin, M. J.
    ANNALS OF ONCOLOGY, 2008, 19 (04) : 814 - 820
  • [27] Expression of XIAP protein in neuroblastomas and ewing sarcoma family tumors
    Galli, S. B.
    Tsokos, M.
    LABORATORY INVESTIGATION, 2007, 87 : 312A - 312A
  • [28] Expression of XIAP protein in neuroblastomas and Ewing sarcoma family tumors
    Galli, S. B.
    Tyokos, M.
    MODERN PATHOLOGY, 2007, 20 : 312A - 312A
  • [29] TPD52 Significance in a Large Series of Ewing's Sarcoma Family of Tumors (ESFT).
    Llombart-Bosch, A.
    Machado, I.
    Calabuig-Farinas, S.
    Lopez-Guerrero, J. A.
    Alberghini, M.
    Scotlandi, K.
    Picci, P.
    Byrne, J.
    MODERN PATHOLOGY, 2011, 24 : 18A - 18A
  • [30] Prognostic significance of serum LDH in Ewing's sarcoma of bone
    Bacci, G
    Ferrari, S
    Longhi, A
    Rimondini, S
    Versari, M
    Zanone, A
    Forni, C
    ONCOLOGY REPORTS, 1999, 6 (04) : 807 - 811